Compare Nomura Holdings Inc (NMR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Smith & Nephew plc — how do they compare? Nomura Holdings Inc trades at $10.84 (market cap $31.31B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Nomura Holdings Inc is far larger — about 2.7× Smith & Nephew plc's market cap, and Nomura Holdings Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| NMR | SNN | |
|---|---|---|
Market Cap | $31.31B | $11.63B |
Sector | Financials | Health |
52-Week High | $10.65 | $38.53 |
52-Week Low | $6.73 | $27.80 |
Dividend Yield | 3.05% | 2.85% |
Enterprise Value | — | $14.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $10.63, down 0.19% on the day, with a bullish technical signal driven by moving averages. Recent earnings show mixed quarterly performance but strong annual growth, with revenue reaching $1.66 trillion in 2025 and net income margin at 20.4%. The stock is supported by positive momentum coverage and a solid ROE of 11.03%.
Outlook remains favorable due to valuation metrics like a P/E of 12.46 and bullish analyst sentiment, though risks include volatile cash flows and rising debt-to-asset ratios. Investment opportunity lies in continued wholesale segment growth and ROE expansion, balanced by execution risks in a competitive financial sector.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
